Protagonist Therapeutics (PTGX) EPS (Weighted Average and Diluted) (2021 - 2025)
Protagonist Therapeutics (PTGX) has disclosed EPS (Weighted Average and Diluted) for 5 consecutive years, with -$0.7 as the latest value for Q4 2025.
- Quarterly EPS (Weighted Average and Diluted) fell 134.83% to -$0.7 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.06 through Dec 2025, down 148.7% year-over-year, with the annual reading at -$2.05 for FY2025, 148.46% down from the prior year.
- EPS (Weighted Average and Diluted) hit -$0.7 in Q4 2025 for Protagonist Therapeutics, down from -$0.62 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $3.26 in Q1 2024 to a low of -$0.84 in Q2 2022.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.23 across 5 years, with a median of -$0.6 in 2023.
- Biggest five-year swings in EPS (Weighted Average and Diluted): surged 586.57% in 2024 and later tumbled 134.83% in 2025.
- Year by year, EPS (Weighted Average and Diluted) stood at -$0.77 in 2021, then increased by 9.09% to -$0.7 in 2022, then surged by 174.29% to $0.52 in 2023, then skyrocketed by 286.54% to $2.01 in 2024, then tumbled by 134.83% to -$0.7 in 2025.
- Business Quant data shows EPS (Weighted Average and Diluted) for PTGX at -$0.7 in Q4 2025, -$0.62 in Q3 2025, and -$0.55 in Q2 2025.